Compass Therapeutics Inc. (CMPX)
CMPX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/0001171843-26-001337-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CMPX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001738021 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$66.5M |
| Operating income | -$72.8M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $30.6M |
| Total assets | $219.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $41.5M cash; operating cash flow -$15.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 180,087,915 (2026-11-05); 177,862,102 a year earlier; 127,486,326 three years earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2025-12-30 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CohnReznick LLP, Melville, New York, United States | PCAOB Form AP 2026-03-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $78K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$27.2M | -$16.3M | $41.5M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | Not filed | -$25.2M | -$14.7M | $35.5M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2026 2026-03-31 | Not filed | -$18.3M | -$17.3M | $55.2M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2025 2025-12-31 | $0 | -$15.7M | -$13.3M | $30.6M | No debt tags | $0 | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | $0 | -$14.3M | -$10.8M | $46.2M | No debt tags | Needs four quarters | 10-Q 2025-11-05 |
| Q2 2025 2025-06-30 | $0 | -$19.9M | -$11.8M | $22.9M | No debt tags | Needs four quarters | 10-Q 2025-08-11 |
| Q1 2025 2025-03-31 | Not filed | -$16.6M | -$13.2M | $41.0M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2024 2024-12-31 | $0 | -$15.0M | -$9.2M | $43.5M | No debt tags | $850K | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2025-12-30 |
| Latest annual report FORM 10-K | 10-K | 2026-03-05 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-09 |
| Latest current report FORM 8-K | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 362 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.0% |
| 1 month | -9.7% |
| 3 months | -65.8% |
| Year to date | -85.6% |
| 1 year | -83.8% |
| From 52-week high | -88.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LENZ | LENZ Therapeutics Inc. | $3.82 | -7.51% | $120.0M |
| CRDL | Cardiol Therapeutics Inc. Class A Common Shares | $0.9798 | -2.02% | $125.1M |
| ENGN | enGene Therapeutics Inc. | $1.89 | -21.58% | $126.7M |
| ARMP | Armata Pharmaceuticals Inc. | $2.99 | -22.74% | $111.2M |
| ZURA | Zura Bio Limited | $1.08 | -12.90% | $104.0M |
| FATE | Fate Therapeutics Inc. | $1.14 | -10.94% | $138.6M |
| VYGR | Voyager Therapeutics Inc. | $1.63 | -5.78% | $101.4M |
| MOLN | Molecular Partners AG | $2.70 | -8.21% | $101.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier